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ABSTRACT 
 
Gastric cancer is one of the major causes of cancer-related deaths worldwide, and 
the 5-year overall survival for patients with advanced gastric cancer remains very poor.  
The molecular mechanisms of gastric carcinogenesis are still not fully understood, but 
the importance of epigenetic alterations is now clear.  Therefore, in this study, I aimed i) 
to develop a molecular marker to assess the cancer cell fraction in any DNA sample, 
which will facilitate investigations of molecular mechanisms, and ii) to develop a 
marker that can predict gastric cancers that will respond to DNA demethylating agents.  
To establish a DNA methylation marker to estimate the cancer cell fraction, I isolated 
genomic regions that were specifically methylated in gastric cancer cells.  I further 
identified OSR2, PPFIA3, and VAV3 as barely methylated in normal cells and highly 
methylated in cancer cells.  The cancer cell fraction assessed by the panel of these 
three genes showed good correlation with that assessed by the TP53 mutant allele 
frequency in 13 gastric cancers.  After correction of the gastric cancer cell fraction, 
unsupervised clustering analysis of the genome-wide DNA methylation profiles yielded 
clearer clustering.  To identify a sensitivity marker to 5-aza-2ʹ-deoxycytidine 
(5-Aza-CdR), I first identified six and seven gastric cancer cell lines that were sensitive 
and resistant, respectively, to 5-Aza-CdR.  By comprehensive gene expression analysis, 
LINC00162 was identified to be highly expressed in sensitive cell lines.  Knock-down 
of LINC00162 in sensitive cell lines decreased their sensitivity to 5-Aza-CdR, whereas 
its overexpression in resistant cell lines increased their sensitivity.  In vivo experiment, 
overexpression of LINC00162 increased the sensitivity to 5-Aza-CdR.  Taken together, 
our new DNA methylation marker for cancer cell fractions will help advance the 
molecular characterization of gastric cancers, and our new sensitivity marker, 
LINC00162, may be useful to stratify gastric cancer patients for 5-Aza-CdR treatment.   
